6-甲基吡啶-3-碳酰肼 | 197079-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-甲基吡啶-3-碳酰肼
• 英文名称: 6-methylpyridine-3-carbohydrazide
• 英文别名: 6-methylnicotinoyl hydrazide；6-methylnicotinoylhydrazide；6-methylnicotinohydrazide；6-methyl-nicotinic acid hydrazide；6-Methyl-nicotinsaeure-hydrazid；6-methyl-3-pyridinecarbohydrazide
• CAS: 197079-25-7
• 化学式: C₇H₉N₃O
• mdl: MFCD01838565
• 分子量: 151.168
• InChiKey: WXHPYVNOEDALAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  68
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 储存条件：
  应存于室温、避光环境中，并在惰性气体氛围下保存。

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	N-(cinnamylideneamino)-6-methylpyridine-3-carboxamide	341986-51-4	C16H15N3O	265.315
  6-甲基-3-吡啶羰基叠氮化物	6-methyl-nicotinoyl azide	64038-04-6	C7H6N4O	162.151
  ——	N'-[(4-chlorophenyl)methylene]-6-methylnicotinohydrazide	——	C14H12ClN3O	273.722
  ——	N'-[(4-bromophenyl)methylene]-6-methylnicotinohydrazide	——	C14H12BrN3O	318.173
  ——	N-[(4-fluorophenyl)methylideneamino]-6-methylpyridine-3-carboxamide	328542-27-4	C14H12FN3O	257.267
  ——	(2-thienylmethylene)-6-methylnicotinohydrazide	——	C12H11N3OS	245.305
  ——	N-[(3-bromophenyl)methylideneamino]-6-methylpyridine-3-carboxamide	328541-93-1	C14H12BrN3O	318.173
  ——	N-[[4-(dimethylamino)phenyl]methylideneamino]-6-methylpyridine-3-carboxamide	328542-01-4	C16H18N4O	282.345
  ——	6-methyl-N-phenyl-nicotinamide	5605-24-3	C13H12N2O	212.251
  ——	N-[[4-(diethylamino)phenyl]methylideneamino]-6-methylpyridine-3-carboxamide	341986-50-3	C18H22N4O	310.399

反应信息

• 作为反应物：
  描述：

  6-甲基吡啶-3-碳酰肼 在 盐酸 、 potassium nitrite 、 乙醚 作用下， 生成 6-methyl-N-phenyl-nicotinamide
  参考文献：
  名称：

  Graf, Journal fur praktische Chemie (Leipzig 1954), 1932, vol. <2> 133, p. 36,49

  摘要：

  DOI：
• 作为产物：
  描述：

  5-乙基-2-甲基-吡啶 在 硫酸 、 硝酸 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 6-甲基吡啶-3-碳酰肼
  参考文献：
  名称：

  Synthesis, characterization and molecular docking studies of some new 1,3,4-oxadiazolines bearing 6-methylpyridine moiety for antimicrobial property

  摘要：

  A new series of 3-acetyl-2-aryl-2H/methy1-5[3-(6-methylpyridinyl)]-2,3-dihydro-[1,3,4]-oxadiazole derivatives were synthesized from 6-methyl nicotinate through a multistep reaction sequence. The structures of newly synthesized compounds were established on the basis of elemental analysis, IR, H-1 NMR, C-13 NMR and mass spectral data. Three dimensional structure of the compound 5f was further confirmed by single crystal X-ray analysis. All the synthesized compounds were screened for their antimicrobial activity and antioxidant activity. The final compounds were subjected to molecular docking studies for the inhibition of enzyme L-glutamine: D-fructose-6-phosphate amidotransferase [GlcN-6-P] (EC 2.6.1.16). The in silico molecular docking results are matching with the in vitro studies and they may be considered as good inhibitor of GlcN-6-P synthase.6-methylpyridine. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.07.019

文献信息

• [EN] TRIAZOLE AGONISTS OF THE APJ RECEPTOR<br/>[FR] TRIAZOLES AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2016187308A1

  公开（公告）日：2016-11-24

  Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一种的立体异构体，或它们的混合物是APJ受体的激动剂，并可用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构，其中变量的定义在此提供。
• New pyrazole derivatives containing 1,2,4-triazoles and benzoxazoles as potent antimicrobial and analgesic agents
  作者：A.M. Vijesh、Arun M. Isloor、Prashanth Shetty、S. Sundershan、Hoong Kun Fun

  DOI：10.1016/j.ejmech.2012.12.057

  日期：2013.4

  their excellent therapeutic properties. Present paper describes about the synthesis of three series of new 1,2,4-triazole and benzoxazole derivatives containing substituted pyrazole moiety (11a–d, 12a–d and 13a–d). The newly synthesized compounds were characterized by spectral studies and also by C, H, N analyses. All the synthesized compounds were screened for their analgesic activity by the tail flick

  唑类化合物以其优异的治疗性能而闻名。本论文描述了含有取代的吡唑部分（11a-d，12a-d和13a-d）的三个系列的新的1,2,4-三唑和苯并恶唑衍生物的合成。通过光谱研究以及C，H，N分析对新合成的化合物进行了表征。通过甩尾法筛选所有合成的化合物的镇痛活性。新衍生物的抗菌活性也通过最小稀释浓度（MIC）通过系列稀释法进行。结果表明，化合物11c 在吡唑部分上具有2，5-二氯噻吩取代基和三唑环的化合物具有显着的止痛和抗菌活性。
• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• [EN] 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE UTILISÉS COMME INHIBITEURS D'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE LES COMPRENANT
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2021210857A1

  公开（公告）日：2021-10-21

  The present invention relates to a novel compound having a histone deacetylase 6 (HDAC6) inhibitory activity, an optical isomer thereof or a pharmaceutically acceptable salt thereof, the use thereof for preparing a therapeutic medicament, a pharmaceutical composition containing the same, and a treatment method using the composition, and a preparation method thereof. The novel compound, the optical isomer thereof, or the pharmaceutically acceptable salt thereof according to the present invention has the HDAC6 inhibitory activity, which is effective in the prevention or treatment of HDAC6-mediated diseases including cancer, inflammatory diseases, autoimmune diseases, neurological or neurodegenerative diseases.

  本发明涉及一种具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其光学异构体或其药学上可接受的盐，以及其用于制备治疗药物、含有该化合物的药物组合物，以及使用该组合物的治疗方法和其制备方法。根据本发明，该新化合物、其光学异构体或其药学上可接受的盐具有HDAC6抑制活性，对预防或治疗包括癌症、炎症性疾病、自身免疫疾病、神经系统或神经退行性疾病在内的HDAC6介导疾病具有有效性。
• [EN] AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS<br/>[FR] DÉRIVÉS D'AZOLE EN TANT QU'INHIBITEURS DE LA VOIE WNT
  申请人：OSLO UNIVERSITY HOSPITAL HF

  公开号：WO2010139966A1

  公开（公告）日：2010-12-09

  The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

  本发明涉及公式I的新化合物，涉及其制备过程，含有这种化合物的药物配方以及它们在治疗中的应用。这些化合物在治疗和/或预防受到Wnt信号通路过度激活影响的疾病或病症中发挥特定作用。例如，它们可用于预防和/或延缓肿瘤细胞的增殖，例如结肠癌等癌症。